Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Analyzes FDA Pilot for Improvements

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

CLL Society writes to FDA in support of its Rare Disease Endpoint Advancement (RDEA) Pilot program. However, we also offer a number of recommendations to strengthen the effort, given that CLL in particular could benefit from FDA’s efforts in this realm. Our heterogeneity, indolence, and response to previous therapies can combine to make endpoints difficult to identify and study. Our recommendations include FDA (a) take a broader approach to identifying needed expertise for the pilot, (b) ask drug sponsors to clearly identify the rare disease a novel endpoint might be applicable to when requesting it for more common conditions, and (c) give preference to promising novel endpoints in life-threatening rare diseases for which existing treatments fail to impact outcomes in later stages.

Read the letter to FDA and all our recommendations:

Download the letter.